2004
DOI: 10.1016/j.jfluchem.2004.09.014
|View full text |Cite
|
Sign up to set email alerts
|

Fluorinated peptidomimetics: synthesis, conformational and biological features

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
17
0

Year Published

2006
2006
2013
2013

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 59 publications
(17 citation statements)
references
References 36 publications
0
17
0
Order By: Relevance
“…The latter is comparable in size with the perfluoroisopropyl group 32. Rotational energy studies on ortho,ortho ′‐disubstituted biphenyl derivatives suggest that the CF 3 group supports a volume slightly larger than the volume of isopropyl,33 whereas X‐ray crystal data put its volume closer to that of an isobutyl group 34…”
Section: The Halogen Substituent Effectmentioning
confidence: 98%
“…The latter is comparable in size with the perfluoroisopropyl group 32. Rotational energy studies on ortho,ortho ′‐disubstituted biphenyl derivatives suggest that the CF 3 group supports a volume slightly larger than the volume of isopropyl,33 whereas X‐ray crystal data put its volume closer to that of an isobutyl group 34…”
Section: The Halogen Substituent Effectmentioning
confidence: 98%
“…2) [12]. X-ray crystallographic analyses of pepstatin A and the fluorinated analog 5 bound to plasmepsin II showed a very similar conformation for both compounds demonstrating that the trifluoromethyl group can be successfully used to mimic an isobutyl moiety [12,15]. The modified inhibitor, bis-trifluoromethyl pepstatin 5 did not show any effect on proteolytic activity of HIV-protease at concentrations up to 150 µM, but a much stronger activity was found towards plasmepsin II, an aspartic protease of the malaria-causing protozoa, Plasmodium falciparum [12,15].…”
Section: The Cf 3 Moietymentioning
confidence: 95%
“…Trifluoromethyl moiety was incorporated into Pepstatin A, a subnanomolar inhibitor of many aspartyl proteases by replacing the isobutyl group to produce compound 5 (Fig. The modified inhibitor, bis-trifluoromethyl pepstatin 5 did not show any effect on proteolytic activity of HIV-protease at concentrations up to 150 µM, but a much stronger activity was found towards plasmepsin II, an aspartic protease of the malaria-causing protozoa, Plasmodium falciparum [12,15]. The substitution was performed to investigate the biological activity of the fluorinated inhibitor against several aspartyl proteases including HIV-protease, a protease for which pepstatin A has no affinity.…”
Section: The Cf 3 Moietymentioning
confidence: 99%
“…Given the ubiquitous nature of α‐amino acids in biologically active compounds, it is not surprising that there have been a number of reports describing the stereoselective incorporation of the trifluoromethyl group into simple amino acids, as well as more complex polypeptides 3. In this way, Zanda and co‐workers have shown that 2,2,2‐trifluoroethylamines can act as a nonbasic amide surrogate, and have made use of this strategy in the development of novel peptidomimetics 3ae. This approach has also recently been employed in the development of potent and selective cathepsin K inhibitors for the treatment of osteoporosis, where the planar amide functionality of the parent compound A has been replaced with a stereogenic 2,2,2‐trifluoroethyl moiety (Scheme 1) 4.…”
Section: Methodsmentioning
confidence: 99%